Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
This is a multi center, open-label, single dose, safety study. Approximately 9 to 15 participants with open-angle glaucoma are assigned into 3 sequential dose-levels and will receive ANX007 administered as single, IVT injections.
Epistemonikos ID: f97b2df7782bccbc030403c370b9c992a6193ba5
First added on: May 21, 2024